Clinical Trials · NCT03798054
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 878
- Start date
- Feb 2019
- Locations
- 79 sites, 4 countries
- Primary endpoint
- Change in HbA1c